Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price & Analysis

Rhythm Pharmaceuticals, Inc. (RYTM) closed at USD 90.9 on Thursday, October 22, 2026, up 2.57% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 88.62; the Oct 22, 2026 session ranged USD 87.59–90.95 on volume of 516,393 shares. Market capitalization is $6.26B, with a 52-week range of USD 74.5–122.2 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:13 UTC.

Also available as compact Markdown for AI agents: nexqual.com/RYTM.md

Key facts (RYTM)

• Last four reported quarters (through Jun 30, 2026): revenue $240M, net income -$205M (-85.6% margin) (SEC filings).
• Insider open-market sales, last ~7 months: 8 Form 4 filings, $32.9M; 1 not under a Rule 10b5-1 plan ($428K); 1 by opportunistic insiders (0 outside 10b5-1 plans), 3 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.84 on a 1–5 scale) (19 analysts), mean target USD 140.29 (range 120–160).
• Total return with dividends: 1Y -16.7% vs S&P 500 +14.9%; 5Y +727.9% vs S&P 500 +80.3%.
• Next earnings: 2026-11-03, EPS estimate USD -0.74, revenue estimate $84.5M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RYTM)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (RYTM)

P/S 26.1x · EV/Sales 25.1x · P/B 60.8x · Earnings yield -3.28% · Net cash $225M · EV $6.03B

Insider sales (SEC Form 4, open-market, last ~7 months) (RYTM)

7 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (RYTM)

Consensus Buy (mean 1.84 on a 1–5 scale), 19 analysts; mean target USD 140.29 (low 120, high 160).

Rating changes, last 120 days:

Total return (dividends reinvested) (RYTM)

RYTM revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

RYTM suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

RYTM customer concentration

In the period ended Jun 30, 2026, a single direct customer accounted for 72% of revenue, per the company's 10-Q filed Aug 4, 2026. The company does not name it.

RYTM company outlook (results filed Aug 4, 2026)

• “Financial Guidance: For the year ending December 31, 2026, Rhythm anticipates approximately $363 million to $397 million in Non-GAAP Operating Expenses.”
• “Based on its current operating plans, Rhythm expects that its cash, cash equivalents and short-term investments as of June 30, 2026 will be sufficient to fund the Company's planned operations for at least 24 months.”

Quoted word-for-word from the SEC 8-K results press release.

RYTM analyst estimates and revisions

RYTM options: expected move

Options price a move of about ±11.1% (±$10.13) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±6.8% on average.

30-day implied volatility 42.9% vs 31.3% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:13 UTC)

Technical Analysis (RYTM)

Nexqual's technical model rates RYTM "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:13 UTC.

Analyst Ratings (RYTM)

Wall Street analysts rate RYTM "Buy" based on 19 analysts, with a mean price target of USD 140.29 (range USD 120–160), per Nexqual as of October 23, 2026 at 09:13 UTC.

Earnings (RYTM)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:13 UTC.

Financials & Fundamentals (RYTM)

Source: Nexqual, October 23, 2026 at 09:13 UTC.

Financial Health Score (RYTM)

Nexqual rates Rhythm Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:13 UTC.

Ownership (RYTM)

Source: Nexqual, October 23, 2026 at 09:13 UTC.

Leadership (RYTM)

Rhythm Pharmaceuticals, Inc. is led by David P. Meeker, Chairman, President & CEO, per Nexqual as of October 23, 2026 at 09:13 UTC.

Major Backers & Investors (RYTM)

Notable institutional backers of Rhythm Pharmaceuticals, Inc. include RA Capital Management, L.P., Baker Bros. Advisors, LP, Primecap Management Company, according to Nexqual as of October 23, 2026 at 09:13 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:13 UTC.

From Rhythm Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• We have established a strong global foundation with IMCIVREE (setmelanotide), which has achieved regulatory approvals and marketing authorization, reimbursed access or named patient sales in more than 25 countries, including the United States, the European Union and the United Kingdom.
• The EMA confirmed validation of our Type II variation submission to the Marketing Authorization Application (MAA) for setmelanotide for the same indication.
• We also expect EMANATE results, in combination with results from our completed DAYBREAK trial, to advance our understanding of which genetic variants are associated with loss of function and to inform on our approach to future clinical development.

Legal & Regulatory Risks (Item 1A, quoted)

• We may not be able to maintain the benefits of orphan drug exclusivity, or that the FDA or the EC or Japan's Ministry of Health, Labour and Welfare will grant orphan designations for setmelanotide for other uses. In addition, orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.
• We may never receive regulatory approval to market setmelanotide outside of the United States, Canada, the European Union and the United Kingdom.
• We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability.
• We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:13 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt